Literature DB >> 11594623

Acinetobacter ursingii sp. nov. and Acinetobacter schindleri sp. nov., isolated from human clinical specimens.

A Nemec, T De Baere, I Tjernberg, M Vaneechoutte, T J van der Reijden, L Dijkshoorn.   

Abstract

The taxonomic status of two recently described phenetically distinctive groups within the genus Acinetobacter, designated phenon 1 and phenon 2, was investigated further. The study collection included 51 strains, mainly of clinical origin, from different European countries with properties of either phenon 1 (29 strains) or phenon 2 (22 strains). DNA-DNA hybridization studies and DNA polymorphism analysis by AFLP revealed that these phenons represented two new genomic species. Furthermore, 16S rRNA gene sequence analysis of three representatives of each phenon showed that they formed two distinct lineages within the genus Acinetobacter. The two phenons could be distinguished from each other and from all hitherto-described Acinetobacter (genomic) species by specific phenotypic features and amplified rDNA restriction analysis patterns. The names Acinetobacter ursingii sp. nov. (type strain LUH 3792T = NIPH 137T = LMG 19575T = CNCTC 6735T) and Acinetobacter schindleri sp. nov. (type strain LUH 5832T = NIPH 1034T = LMG 19576T = CNCTC 6736T) are proposed for phenon 1 and phenon 2, respectively. Clinical and epidemiological data indicate that A. ursingii has the capacity to cause bloodstream infections in hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594623     DOI: 10.1099/00207713-51-5-1891

Source DB:  PubMed          Journal:  Int J Syst Evol Microbiol        ISSN: 1466-5026            Impact factor:   2.747


  48 in total

1.  Naturally transformable Acinetobacter sp. strain ADP1 belongs to the newly described species Acinetobacter baylyi.

Authors:  Mario Vaneechoutte; David M Young; L Nicholas Ornston; Thierry De Baere; Alexandr Nemec; Tanny Van Der Reijden; Emma Carr; Ingela Tjernberg; Lenie Dijkshoorn
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  Lack of evidence for "Acinetobacter septicus" as a species different from Acinetobacter ursingii?

Authors:  Alexandr Nemec; Martin Musílek; Mario Vaneechoute; Enevold Falsen; Lenie Dijkshoorn
Journal:  J Clin Microbiol       Date:  2008-08       Impact factor: 5.948

3.  Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region.

Authors:  Hsien Chang Chang; Yu Fang Wei; Lenie Dijkshoorn; Mario Vaneechoutte; Chung Tao Tang; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

4.  Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens.

Authors:  Laurent Dortet; Patrick Legrand; Claude-James Soussy; Vincent Cattoir
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

5.  Detection of New Delhi metallo-β-lactamase (encoded by blaNDM-1) in Acinetobacter schindleri during routine surveillance.

Authors:  Patrick McGann; Michael Milillo; Robert J Clifford; Erik Snesrud; Lindsay Stevenson; Michael G Backlund; Helen B Viscount; Reyes Quintero; Yoon I Kwak; Michael J Zapor; Paige E Waterman; Emil P Lesho
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

6.  Bacteremia caused by Acinetobacter ursingii.

Authors:  Julien Loubinoux; Liliana Mihaila-Amrouche; Anne Le Fleche; Etienne Pigne; Gerard Huchon; Patrick A D Grimont; Anne Bouvet
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

7.  First case of Pseudoclavibacter bifida bacteremia in an immunocompromised host with chronic obstructive pulmonary disease (COPD).

Authors:  Matthijs Oyaert; Thierry De Baere; Joke Breyne; Emmanuel De Laere; Stan Mariën; Peter Waets; Wim Laffut
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

8.  Do biofilm formation and interactions with human cells explain the clinical success of Acinetobacter baumannii?

Authors:  Anna de Breij; Lenie Dijkshoorn; Ellen Lagendijk; Joke van der Meer; Abraham Koster; Guido Bloemberg; Ron Wolterbeek; Peterhans van den Broek; Peter Nibbering
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

9.  Acinetobacter septicus sp. nov. association with a nosocomial outbreak of bacteremia in a neonatal intensive care unit.

Authors:  Abdullah Kilic; Haijing Li; Alexander Mellmann; Ahmet C Basustaoglu; Mustafa Kul; Zeynep Senses; Hakan Aydogan; Charles W Stratton; Dag Harmsen; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2007-12-26       Impact factor: 5.948

Review 10.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.